Cantor Fitzgerald initiated coverage of Perspective Therapeutics with an Overweight rating.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CATX:
- Perspective Therapeutics to Participate at Upcoming May Investor Conferences
- Perspective Therapeutics to Provide Recent Business Highlights and Report First Quarter 2024 Financial Results
- Perspective Therapeutics selected by FDA to participate in CDRP program
- Perspective Therapeutics Selected by FDA to Participate in the CDRP Program to Expedite Chemistry, Manufacturing, and Controls Development Readiness for VMT-α-NET in NETs
- Perspective Therapeutics price target raised to $1.70 from $1.20 at B. Riley